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Culprit Artery, Ischemic Time Window, and Severity of
Injury
Sander A.J. Damen,a,† Gilbert E. Cramer,a,*,† Hendrik-Jan Dieker,a Helmut Gehlmann,a
Ton J.M. Oude Ophuis,b Wim R.M. Aengevaeren,c Marion Fokkert,d Freek W.A. Verheugt,a
Harry Suryapranata,a Alan H. Wu,e Xander M.R. van Wijk,e,f and Marc A. Brouwera
BACKGROUND: Troponin composition characterization
has been implicated as a next step to differentiate among
non-ST elevation myocardial infarction (NSTEMI)
patients and improve distinction from other conditions
with troponin release. We therefore studied coronary
and peripheral troponin compositions in relation to clin-
ical variables of NSTEMI patients.
METHODS: Samples were obtained from the great car-
diac vein (GCV), coronary sinus (CS), and peripheral
circulation of 45 patients with NSTEMI. We measured
total cTnI concentrations, and assessed both complex
cTnI (binary cTnIC þ all ternary cTnTIC forms), and
large-size cTnTIC (full-size and partially truncated
cTnTIC). Troponin compositions were studied in rela-
tion to culprit vessel localization (left anterior descend-
ing artery [LAD] or non-LAD), ischemic time window,
and peak CK-MB value.
RESULTS: Sampling occurred at a median of 25 hours af-
ter symptom onset. Of total peripheral cTnI, a median
of 87[78-100]% consisted of complex cTnI; and 9[6-
15]% was large-size cTnTIC. All concentrations (total,
complex cTnI, and large-size cTnTIC) were signifi-
cantly higher in the CS than in peripheral samples
(P< 0.001). For LAD culprit patients, GCV concentra-
tions were all significantly higher; in non-LAD culprit
patients, CS concentrations were higher. Proportionally,
more large-size cTnTIC was present in the earliest sam-
pled patients and in those with the highest CK-MB
peaks.
CONCLUSIONS: In coronary veins draining the infarct
area, concentrations of both full-size and degraded tro-
ponin were higher than in the peripheral circulation.
This finding, and the observed associations of troponin
composition with the ischemic time window and the ex-
tent of sustained injury may contribute to future charac-
terization of different disease states among NSTEMI
patients.
Introduction
Cardiac troponin (cTn) is uniquely present inside cardi-
omyocytes consisting of two cardiospecific isoforms
(cTnT and cTnI) and one non-cardiospecific form
(TnC). After myocardial infarction (MI), circulating
cTn primarily consists of complex forms (1–6).
Recently, cTn composition was described to arise from
a stepwise transformation of full-size ternary cTnT-
cTnI-cTnC complex (cTnTIC) into smaller sized com-
plexes and fragments of cTn (5). As a future develop-
ment in biomarker diagnostics, characterization of
patterns of cTn composition may contribute to diagnos-
tic differentiation and could be indicative of underlying
disease status (7–9). However, direct evidence that links
cTn composition to diseased myocardium in the setting
of MI is lacking. Interestingly, a connection between
cTn composition and disease status might exist, as inci-
dental observations showed a relation with the ischemic
time window (4, 5, 9–12) and injury severity (13–15).
The difficulty of these investigations was that laboratory
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analyses were complex, time consuming, and were
performed in a limited number of MI patients.
Additionally, blood was sampled remote to the injured
myocardium in all but one study. In that study, cTnT
composition was assessed in the coronary venous system
(CVS) and a concentration gradient was observed for all
known cTnT fragments towards the peripheral circula-
tion (10) .
In view of this, we extended our analyses on cTn
composition in blood obtained from various sites within
the CVS. With the use of 2 recently developed precom-
mercial assays, cTn composition could be studied in a
larger-sized cohort of non-ST elevation MI (NSTEMI)
patients. Using a high-sensitive platform complex cTnI
(i.e., full-size, partially truncated, and low molecular
weight cTnTIC [LMW cTnTIC], and binary cTnI-
cTnC [cTnIC]), and large-size cTnTIC complexes (i.e.,
full-size or partially truncated cTnTIC) were measured,
in addition to total cTnI (16, 17). The size of the cohort
allowed comparison of patients with left anterior descend-
ing (LAD) or non-LAD culprit arteries, which together
with multiple site CVS sampling allowed linkage of cTn
form concentrations to the area of injured myocardium.
In addition, subgroup comparisons were made of severity
of sustained injury and ischemic time interval.
Methods and Materials
PATIENT POPULATION
For the present analysis we studied a selection of
NSTEMI patients who participated in the TRAMICI
study (TRanscardiac Assessment of Myocardial Injury
and Coronary Inflammation). TRAMICI is a biomarker
study in NSTEMI patients, including multi-site CVS
blood sampling and serial peripheral blood samples.
This study aimed to assess and compare markers of
myocardial injury and inflammation in samples from
areas draining blood from infarcted and non-infarcted
regions. For inclusion, patients were eligible in case of
a NSTEMI with a rising cTn and significant coronary
artery disease at coronary angiography (CAG). Main ex-
clusion criteria were: indication for immediate percuta-
neous coronary intervention (PCI), prior acute coronary
syndrome, coronary artery revascularization in the last
3 months, or hemodynamic instability. Patients with
ST-elevation myocardial infarction were excluded, to
ensure restoration of coronary flow as soon as possible
without delays related to informed consent for and
execution of a rather comprehensive study protocol.
The full lists of inclusion and exclusion criteria have
been described elsewhere (18).
Participants underwent routine catheterization
(including left ventricular angiogram) and study proce-
dures at the catheterization laboratory of the Radboud
University Medical Center (Nijmegen, The Netherlands).
After CAG and upon identification of the culprit coro-
nary artery by the interventional cardiologist, patients
were included and study procedures were started. Oral
informed consent was obtained prior to CAG, and writ-
ten informed consent was provided afterwards. The local
ethical committee (2004-186) of the Radboud University
Medical Center approved the TRAMICI protocol. Study
procedures were in accordance with the Declaration of
Helsinki.
For the present analysis we selected a subgroup of
patients fulfilling the following criteria: 1) a definite cul-
prit coronary artery at CAG; 2) availability of a sample
from the coronary sinus (CS) and the great cardiac vein
(GCV).
CAG ANALYSIS
Prior to biomarker analyses, a team of cardiologists
performed a standardized evaluation of wall motion ab-
normalities of the left ventricle, lesion characteristics,
and coronary flow to identify the culprit lesion. Of
the patients in whom the culprit lesion was different
compared to what was decided by the interventional
cardiologist, a third evaluation was performed by an in-
dependent cardiologist naive to all data. Upon agree-
ment with either of the 2 previous evaluations, the
culprit artery was defined accordingly. If not, the patient
was classified as culprit unknown, and blood was not
analyzed. For the present analysis we allocated patients
to either having a culprit lesion located in the left ante-
rior descending artery (LAD) or in a non-LAD location
(circumflex or right coronary artery).
STUDY PROCEDURES
The CVS anatomy was recorded during CAG by film-
ing the complete washout of contrast dye. CVS access
was gained by means of a right-sided catheterization
procedure. A Terumo wire (Terumo Europe NV) and
CHAMP multipurpose catheter (Medtronic) were used
for CVS cannulation and blood sampling.
CVS samples. Supplemental Fig. 1 presents a schematic
representation of the sampling protocol. After cannula-
tion of the CVS, the CHAMP catheter was advanced
into the GCV. A baseline blood sample at the GCV
(GCVT0) represents a selective measure of biomarkers
from injured anteroseptal myocardium in patients with
an LAD culprit lesion. After sampling the GCV, the
CHAMP catheter was pulled back and placed distal in
the CVS, preferably as close to the point where the mid-
dle cardiac vein merges with the CS, but always distal
from the second posterolateral vein for the second base-
line sample from the CS (CST0).
The protocol specified the procedures for blood
sampling as follows. First, the position of the catheter
was confirmed using an injection with contrast dye in
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the CVS. Second, the catheter was flushed, and the blood
was allowed to run freely from the catheter end for a few
seconds to ensure sufficient blood reflux. Third, a first
blood sample of 3-4 mL was drawn to perform immedi-
ate blood gas analysis to double check the catheter posi-
tion. Fourth, the blood sample of interest was obtained.
Peripheral venous (PV) blood samples. After removal of
the CHAMP catheter, peripheral blood samples were
obtained from the femoral venous sheath (PVT0).
Follow-up samples. Finally, at 6 and 12 hours post-
procedure, additional venous samples were obtained
from a peripheral vein (PVT6 and PVT12).
Collected blood samples were divided over serum
tubes, immediately centrifuged, divided in 250mL ali-
quots, and stored at -80 C until thawed for further analy-
sis. To prevent potential effects of repeated freeze-thaw
cycling a separate aliquot for each analysis was used.
BIOMARKER MEASUREMENTS
Figure 1 depicts the cTnI forms of interest, determined
with the assays that are described into more detail
below.
Three assays were used to determine the different
cTn compositions in our NSTEMI patients: 1) For total
cardiac troponin I (a combination of complex and non-
complex forms) the high-sensitivity cardiac troponin I
Pylon immunoassay (ET Healthcare) was used; it has
been previously described (16). This assay uses a capture
antibody targeting amino acid residues 27–40, and a
detection antibody which recognizes cTnI amino acids
residues 41–49; 2) To measure complex cTnI (i.e., com-
plexes of full-size cTnTIC, partially truncated cTnTIC
and LMW cTnTIC, and binary cTnIC), the same
Pylon assay analyzer platform was used applying a differ-
ent capture antibody with specificity for complex cTnI:
20C6 (Hytest Ltd). This antibody recognizes cTnIC
and cTnTIC complexes, whereas noncomplexed cTnI
Fig. 1. cTnI forms of interest with the different capture and detection antibodies. Total cTnI: capture cTnI aar 27–40 and detec-
tion cTnI aar 41–49. Complex cTnI: capture 20C6 and detection cTnI aar 41–49. Large-size cTnTIC complexes: capture 20C6
and detection TnT1C11 (cTnT aar 171–190). Aar: amino-acid residue; cTn: cardiac troponin; LMW: low molecular weight.
Troponin Composition after Myocardial Infarction
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remains undetected. 3) To determine large-size cTnTIC
complexes (i.e., full-size cTnTIC and partially truncated
cTnTIC) again the Pylon assay analyzer platform was
used to combine the capture antibody 20C6 with a de-
tection antibody that binds cTnT amino acid residues
171–190 (i.e., 1C11 from Hytest). The specificity of
this cTnT antibody is such that this assay detects cTnTIC
complexes with intact cTnT (37 kDa) and its 29 kDa frag-
ment, but not cTnTIC complexes with a smaller-sized
14 kDa cTnT degradation product, previously referred to
as LMW cTnTIC (5). Assay performance characteristics
have been described elsewhere (16, 17). In addition, assay
specificity data are reported in the Supplemental Fig. 2.
CK-MB analysis. Creatinine kinase myocardial brain
(CK-MB) was assessed at baseline, and 6 and 12 hours
thereafter to assess the severity of myocardial injury.
The CK-MB assay was provided to us by Roche
Diagnostics, and analyses were performed on a Cobas
analyzer (Roche). The CK-MB immunoassay has a
lower limit of detection of 0.1 ng/mL. Peak CK-MB
was defined as the highest of the three measurements.
STATISTICAL ANALYSIS
Continuous data were analyzed for Gaussian distribu-
tion and were expressed as medians with interquartile
ranges (IQR). Numerical data were described as a num-
ber with a percentage. Paired data were compared using
the Wilcoxon signed rank tests or related-samples
Friedman’s two-way ANOVA tests whenever appropri-
ate. The Mann-Whitney U test was performed for com-
parisons between unrelated groups. Correlation
coefficients between continuous variables were investi-
gated using Spearman’s Rho. A P-value less than 0.05
was considered statistically significant. All analyses were
performed using IBM SPSS Statistics software (version
22.0, IBM Corp).
Results
A total of 45 out of 71 patients that were included in
the TRAMICI study qualified for biomarker analyses in
the present study (Supplemental Fig. 3). Table 1 shows
baseline clinical and angiographic characteristics. The
LAD was the culprit lesion in 18 patients, while the
other 27 had a non-LAD culprit lesion. The duration
between symptom onset and the start of study proce-
dures was 25 [19–36] hours, with a duration between
hospitalization and study procedures of 21 [13–27]
hours. Peak CK-MB value measured during hospitaliza-
tion was 10.47 [4.19–19.15] ng/mL.
PERIPHERAL CTNI COMPOSITION
Total cTnI concentration at PVT0 was 612 [203–1666]
ng/L, of which 87 [78–100] % was present as complex
cTnI and 9 [6–15] % as large-size cTnTIC. Over time,
total cTnI concentration showed an increase at PVT6
compared to PVT0 (P¼ 0.018), whereas at PVT12 to-
tal cTnI was significantly lower as compared to PVT6
(P¼ 0.013) (Table 2).
As for complex cTnI, in pairwise comparisons abso-
lute median concentrations increased between PVT0
and PVT6 (P¼ 0.024), and were nonsignificantly
different between PVT6 and PVT12 (P¼ 0.052)
(Table 2). Expressed as a proportion of total cTnI, com-
plex cTnI did not change between the different time
points (Fig. 2A).
Absolute median large-size cTnTIC concentrations
decreased between PVT6 and PVT12 (P¼ 0.001) (Table
2), as did large-size cTnTIC as a proportion of total cTnI
between PVT6 and PVT12 (P¼ 0.01) (Fig. 2B).
CORONARY VENOUS SYSTEM VERSUS PERIPHERAL VENOUS
The absolute median CST0 concentrations of total
cTnI, complex cTnI, and large-size cTnTIC were signif-
icantly higher as compared to the PVT0 samples





Male gender 32 (71%)
Smoking 21 (47%)
Hypertension 21 (47%)
Diabetes mellitus 4 (9%)
Hypercholesterolemia 16 (36%)
History of MI 9 (20%)
History of coronary revascularization 5 (11%)
eGFR (mL/min/1.73 m2) 93 [66–115]












Values are medians (interquartile ranges) or numbers (percentages).
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(all: P< 0.001) (Table 2). The relative contribution of
complex cTnI as a proportion of total cTnI was higher
in PVT0 samples as compared to CST0 samples
(P¼ 0.01) (Fig. 2A); for large-size cTnTIC complexes
proportions were lower in the PVT0 as compared to
CST0 (Fig. 2B).
Figure 3 shows absolute median concentrations in
the GCVT0 and CST0 according to localization of the
culprit lesion. In patients with an LAD culprit lesion
(n¼ 18, Fig. 3A), absolute concentrations were higher
in the GCVT0 for total cTnI, complex cTnI, and large-
size cTnTIC complexes as compared to concentrations
in the CST0 (all: P< 0.05). In patients with non-LAD
culprit lesions (n¼ 27, Fig. 3B), absolute concentrations
were higher in the CST0 as compared to concentrations
in the GCVT0 (all: P< 0.01). As a proportion of total
cTnI, proportions of complex cTnI were 81 [74–94]%
and 82 [76–96]% (P¼ 0.255) in the GCVT0 and
CST0 respectively, in patients with an LAD culprit le-
sion; for large-size cTnTIC complexes these proportions
were 11 [6–14]% and 13 [9–18]% (P¼ 0.007). In
patients with non-LAD culprit lesions, the proportions
that were observed for complex cTnI were 88 [74–97]%
and 84 [72–92]% (P¼ 0.06), and for large-size
cTnTIC complexes were 8 [5–18]% and 12 [6–17]%
(P¼ 0.464), respectively.
CTNI COMPOSITION IN RELATION TO INJURY SEVERITY AND
ISCHEMIC TIME WINDOW
Injury severity.Total cTnI concentration was 1666
[886–4004]ng/L in the PVT0 of patients with the high-
est peak CK-MB levels (upper 50th percentile), and 278
Table 2. Absolute cTnI concentrations for the total population.
































Median concentrations of cTnI and its subforms in ng/L with interquartile ranges.
*P-value for difference between CST0 and PVT0; †P-value for difference between 3 related groups (PVT0, PVT6, and PVT12); comparison between total cTnI at PVT0 and PVT6:
P¼ 0.018; between PVT6 and PVT12 P¼ 0.013; comparison of complex cTnI between PVT0 and PVT6 P¼ 0.024, between PVT6 and PVT12 P¼ 0.052; comparison between
large-size cTnTIC at PVT0 and PVT6 P¼ 0.518; between PVT6 and PVT12 P¼ 0.001.
Fig. 2. Percentages of cTnI forms relative to the total cTnI concentration. Median percentages of the different cTnI forms with
interquartile ranges. A) Complex cTnI (full-size cTnTIC þ partially truncated cTnTIC þ low molecular weight cTnTIC þ cTnIC) as
proportion of total cTnI. B) Large-size cTnTIC (full-size cTnTICþpartially truncated cTnTIC) as proportion of total cTnI.
Troponin Composition after Myocardial Infarction
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[147–583]ng/L in those with the lowest peak CK-MB lev-
els (lower 50th percentile) (P< 0.001). The median pro-
portions of complex cTnI showed no difference between
the two groups (Fig. 4A). Proportions of large-size
cTnTIC were 14 [9–19]% in the PVT0 of patients with
the highest peak CK-MB levels, and 8 [4–10]% in those
with the lowest (P¼ 0.002) (Fig. 4B). Differences between
these subgroups in proportions of large-size cTnTIC com-
plexes were also observed for GCVT0 and CST0 samples
and persisted at PVT6 and PVT12 (Fig. 4B).
Ischemic time window. Of the patients (n¼ 18) in the low-
est 50th percentile of ischemic time window blood sam-
pling occurred at a median of 19 [15–23] hours after
symptom onset; for patients (n¼ 19) in the highest 50th
percentile sampling occurred at 35 [29–48] hours after
symptom onset. Eight patients were excluded because of
uncertainty regarding time of symptom onset. Total cTnI
concentration in the PVT0 was 1118 [441–3002]ng/L in
patients with the lowest 50th percentile time intervals,
and 583 [147–1228]ng/L in those with the highest
(P¼ 0.210). The median proportions of complex cTnI
showed no difference between patients sampled ‘early’ or
‘late’ (Fig. 4C). Proportions of large-size cTnTIC com-
plexes were 14 [10–19]% in the PVT0 of patients with
the shortest time intervals, and 8 [5–11]% in those with
the longest (P¼ 0.002) (Fig. 4D). Similar differences
in proportions of large-size cTnTIC complexes were
observed for GCVT0 and CST0 samples (Fig. 4D).
The observed higher proportions of large-size
cTnTIC complexes at PVT0 in the group with the
shorter ischemic time window was regardless of the
severity of injury (15% in smaller MIs, 17% in larger
MIs). At PVT6 and PVT12, the difference in propor-
tions of large-size cTnTIC complex in relation to the is-
chemic time interval was no longer present.
Discussion
The present multi-site coronary venous and peripheral
sampling study addresses the cTn composition in a large
well-described series of NSTEMI patients. Using a
highly sensitive immunoassay platform, enabled deter-
mination of total cTnI, complex cTnI and, as a separate
measurement, large-size cTnTIC complexes. In coro-
nary veins draining the infarct area, concentrations of
the large-size cTnTIC complexes, and also of complex
cTnI, were higher than in the peripheral circulation.
Together with the marked differences observed within
the CVS, this indicates that observed degraded forms in
the peripheral circulation are not merely the result
of peripheral breakdown. In addition, proportions of
large-size cTnTIC were higher in patients with shorter
ischemic time windows, and higher CK-MB peaks.
Collectively, these findings may contribute to fu-
ture work on characterization of disease status in
NSTEMI patients according to differences with regard
to cTn composition.
Until now it has remained uncertain where cTn is
transformed after cell injury occurs. The only evidence
of intracellular degradation has been derived from a few
small-sized studies (15, 19–22). In line with intracellular
degradation, several intracellular proteases have been
implicated to selectively proteolyze cTnI and cTnT
(23–27). Recently, in a pilot study on two NSTEMI
patients, concentrations of intact cTnT, but also of
the 29 kDa and smaller 15–18 kDa fragments were
higher in the CVS than in the peripheral circulation
(10). The current analysis of a larger TRAMICI cohort
showed similar results. Higher concentrations of total
cTnI, complex cTnI, and large-size cTnTIC complexes
were observed in the CVS. Additionally, considering
the marked differences within the CVS, the highest
Fig. 3. Absolute cTnI concentrations for patients with a culprit lesion in the LAD or non-LAD. Median concentrations of cTnI and
its subforms in ng/L with interquartile ranges. A) LAD culprit lesion. B) non-LAD culprit lesion.
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concentrations were observed at the site closest to the
injured myocardium. Together with the fact that
complex cTnI and large-size cTnTIC complexes as pro-
portions of total cTnI remained relatively constant be-
tween the GCVT0 and CST0 samples, our observations
are supportive of intracellular breakdown of cTnTIC
complexes prior to release. In a study on cTnI degrada-
tion in post-MI patients, a similar conclusion was drawn
based on ratios of full-size cTnI and its fragments, which
remained unchanged over time (28).
Nonetheless, we recognize that part of cTn degra-
dation may also have occurred in the circulation. As pre-
viously shown, thrombin acts as a proteolytic enzyme
capable of cleaving cTnT at the same amino acid resi-
dues (R68/S69) as intracellular m-calpain (29–31). With
increased thrombin activity in NSTEMI patients, the
chance of cTn degradation inside the circulation is
substantial. Moreover, as observed in the present study,
peripheral blood proportionally contained more
complex cTnI, and less large-size cTnTIC than CVS
samples. This finding may be due to peripheral conver-
sion of large-size cTnTIC into smaller-sized complexes.
Finally, as previously discussed, the effect of thrombin
may also have occurred preanalytically during serum
production (10, 29). Appreciating that this potential ef-
fect applies to both CVS and PV samples, within patient
differences were not likely affected.
Differential cTn patterns were found previously,
which appeared related to the underlying cardiac
condition. First, with increasing injury severity cTnI
and cTnT degradation appeared to be more extensive
(9, 13–15). Second, with longer time-intervals between
Fig. 4. Percentages of cTnI forms relative to the total cTnI concentration according to severity of injury and ischemic time in-
terval. Median percentage of the different cTnI forms with interquartile ranges. *P<0.05 for differences between large and
small; and early and late. A-B) Small MI vs. large MI: patients divided based on peak CK-MB levels in small MI (peak CK-MB
lower 50th percentile) and large MI (peak CK-MB upper 50th percentile) C-D) Early vs. late blood sampling: based on time in-
terval between symptom onset and blood sampling; early time intervals: lower 50th percentile; late time intervals: upper
50th percentile.
Troponin Composition after Myocardial Infarction
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onset of ischemia and cTn assessment, larger cTn frag-
ments predominated in early samples, whereas smaller-
sized fragments were seen later in the MI aftermath (5,
9–12, 14). In two studies which focused on cTn while
in complex with other isoforms, large-size cTnTIC was
more prominent in early stages, and upon disease
progression more cTnIC complexes were seen (5, 6).
As was suggested, disintegration of complexes and deg-
radation of cTnI and cTnT into fragments are regarded
as parallel processes. Troponins are bound in a complex
while cleaved by proteases. With ongoing ischemia,
cTn fragments will dissociate, leaving smaller sized
complexes behind. When these steps occur in a time-
dependent manner, large-size forms might reflect an ear-
lier stage of disease.
In keeping with abovementioned considerations,
we observed higher proportions of large-size cTnTIC in
patients with a shorter ischemic time window.
As for the injury severity, we observed higher large-
size cTnTIC complex proportions in the patients with
the higher peak CK-MB levels. Exploratory analyses on
the small subgroups showed that higher CK-MB levels
were correlated with shorter ischemic time intervals,
which may be related to a higher symptom burden in
case of more severe injury.
Despite a median ischemic time window of more
than a day, we still observed differential release of
cTn according to ischemic time window and sustained
injury severity. In case of earlier sampling, especially in
large-size infarctions, in which the enzymatic capacity
might be inadequate to cause overall degradation, higher
large-size cTnTIC proportions might be expected.
Implications
In this study, we have provided arguments that cTn
composition can be linked to the area of diseased myo-
cardium. As we also linked cTn forms to clinical varia-
bles such as the ischemic time window and injury
severity, a first initiative is presented that underscores
the potential of cTn form status as a direct image of
underlying disease status in NSTEMI patients.
Currently, regular cTn measurements are highly sensi-
tive, but cannot differentiate between NSTEMI
patients. Development of an immunoassay that allows
clinical profiling according to cTn characteristics, could
ultimately identify NSTEMI patients with ‘early’ or
‘late’ damage with potential impact on timely treatment,
and prognosis.
Also, an assay with the capacity to differentiate be-
tween cTn forms might improve specificity in another
way. As shown in recent studies on patients with end-
stage renal disease and healthy marathon runners, cTnT
consisted of small-size fragments of cTnT (32–34). In
this respect, a newly designed assay with a focus on cTn
forms might importantly differentiate between cTn lev-
els due to a type I MI or those seen in other etiologies.
Limitations
We lacked a direct measure of noncomplex cTnI forms
(i.e., free noncomplex cTnI forms). Consequently, the
relative contribution of free cTnI and fragments to the
total composition has not been determined. Given the
fact that at PVT0 87% of total cTnI is considered com-
plex, automatically noncomplex will be 13% of total.
In terms of generalizability, this study only relates
to NSTEMI patients, as patients with ST-elevation
myocardial infarction were excluded, for reasons men-
tioned before. With cardiac catheterization performed at
a median of 25 hours after symptom onset, cTn compo-
sition in the earliest phase after symptom onset has
not been assessed and could prove different with respect
to the ratio of complex and noncomplex forms to
total cTn.
With the use of the current assays with improved
sensitivity, we were able to study patients with a much
smaller infarct-size than in previous reports on this sub-
ject (1–4). However, our study did not include patients
with cTn concentrations just above the 99th percentile
reference limit, and findings can therefore not be in-
ferred to the smallest forms of injury in NSTEMI.
We acknowledge that in addition to our specificity
data (Supplemental materials) we should preferably have
included analyses on partially truncated- and LMW
cTnTIC. However, these cTn complexes are not commer-
cially available. We therefore relied on the recent publica-
tion from Vylegzhanina that unmistakably showed the
presence of these forms using very similar antibodies to
the ones used in the present manuscript (5).
Conclusion
In NSTEMI patients, concentration differences of com-
plex cTnI and large-size cTnTIC within the CVS, and be-
tween the CVS and peripheral samples provide evidence
of linkage of post-MI composition of cTn forms and the
area of diseased myocardium. In addition, the observed
differences in cTnI composition with respect to the time
passed since symptom onset and extent of sustained injury
suggest that, at least partially, cTn composition reflects
disease status of NSTEMI patients. This characterization
may improve biomarker diagnostics and facilitate differen-
tiation between NSTEMI patients, and those with other
etiologies, that may cause release of cTn.
Supplemental Material
Supplemental material is available at Clinical Chemistry
online.
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Nonstandard Abbreviations: cTn, cardiac troponin; cTnT, cardiac
troponin T; cTnI, cardiac troponin I; TnC, noncardiospecific tropo-
nin C; MI, myocardial infarction; cTnTIC: ternary cTnI-cTnT-TnC
complex; CVS: coronary venous system; NSTEMI: non-ST elevation
myocardial infarction; LMW cTnTIC: low molecular weight ternary
cTnTIC complex; cTnIC: binary cTnI-TnC complex; LAD: left ante-
rior descending coronary artery; TRAMICI: TRanscardiac Assessment
of Myocardial Injury and Coronary Inflammation; CAG: coronary an-
giography; PCI: percutaneous coronary intervention; eGFR: estimated
glomerular filtration rate; CS: coronary sinus; GCV: great cardiac vein;
CST0: coronary sinus at baseline; GCVT0: great cardiac vein at base-
line; PV: peripheral vein; PVT0: peripheral vein at baseline; PVT6: pe-
ripheral vein 6 hours after baseline; PVT12: peripheral vein12 hours
after baseline; CK-MB: creatinine kinases myocardial brain; RCX: cir-
cumflex coronary artery; RCA: right coronary artery.
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